Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("Inhibidor phosphodiesterase")

Filter

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 1072

  • Page / 43
Export

Selection :

  • and

Pyrazoloquinolines as PDE10A inhibitors: Discovery of a tool compoundMCELROY, William T; ZHENG TAN; XIAOPING ZHANG et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 3, pp 1335-1339, issn 0960-894X, 5 p.Article

Intérêt thérapeutique d'un inhibiteur de la phosphodiestérase de type 5 et d'un antagoniste sélectif des récepteurs de l' endothéline AALLANORE, Yannick.La Revue de médecine interne (Paris). 2010, Vol 31, pp 8-9, issn 0248-8663, 2 p., HS1Article

Phosphodiesterase inhibitors block the acceleration of skin permeability barrier repair by red lightGOTO, Makiko; IKEYAMA, Kazuyuki; TSUTSUMI, Moe et al.Experimental dermatology. 2011, Vol 20, Num 7, pp 568-571, issn 0906-6705, 4 p.Article

Phosphodiesterase Type 5 Inhibitor Use and Hearing ImpairmentMCGWIN, Gerald.Archives of otolaryngology, head & neck surgery. 2010, Vol 136, Num 5, pp 488-492, issn 0886-4470, 5 p.Article

Role of Growth Factors in Improved Skin Flap Viability Caused by Phosphodiesterase-5 InhibitorBANDERA, Bradley C; PHAM, Thach; HILL-PRYOR, Crystal et al.The American surgeon. 2010, Vol 76, Num 6, pp 614-617, issn 0003-1348, 4 p.Article

Selective phosphodiesterase inhibitors : a promising target for cognition enhancementRENEERKENS, Olga A. H; RUTTEN, Kris; STEINBUSCH, Harry W. M et al.Psychopharmacologia. 2009, Vol 202, Num 1-3, pp 419-443, issn 0033-3158, 25 p.Article

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risksJACKSON, G; ARVER, S; BANKS, I et al.International journal of clinical practice (Esher). 2010, Vol 64, Num 4, pp 497-504, issn 1368-5031, 8 p.Article

Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitorsPACKARD, Garrick K; PAPA, Patrick; MCCARRICK, Margaret A et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 1, pp 747-752, issn 0960-894X, 6 p.Article

Biflavones of Decussocarpus rospigliosii as phosphodiesterases inhibitorsCHAABI, Mehdi; ANTHEAUME, Cyril; WENIGET, Bernard et al.Planta medica. 2007, Vol 73, Num 12, pp 1284-1286, issn 0032-0943, 3 p.Article

Is phosphodiesterase type 5 inhibitor use associated with condom breakage? CommentaryCROSBY, R; YARBER, W. L; SANDERS, S. A et al.Sexually transmitted infections. 2009, Vol 85, Num 5, pp 404-406, issn 1368-4973, 3 p.Article

The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokineticsRAWSON, David J; BALLARD, Stephen; FLOC'H, Marion et al.Bioorganic & medicinal chemistry. 2012, Vol 20, Num 1, pp 498-509, issn 0968-0896, 12 p.Article

Modulation of Morphine-induced Antinociception in Acute and Chronic Opioid Treatment by IbudilastLILIUS, Tuomas O; RAUHALA, Pekka V; KAMBUR, Oleg et al.Anesthesiology (Philadelphia). 2009, Vol 111, Num 6, pp 1356-1364, issn 0003-3022, 9 p.Article

Classification trees based on infrared spectroscopic data to discriminate between genuine and counterfeit medicinesDECONINCK, E; SACRE, P. Y; COOMANS, D et al.Journal of pharmaceutical and biomedical analysis. 2012, Vol 57, Num C, pp 68-75, issn 0731-7085, 8 p.Article

Inhibition of Phosphodiesterases Leads to Prevention of the Mitochondrial Permeability Transition Pore Opening and Reperfusion Injury in Cardiac H9c2 CellsCHANOIT, Guillaume; JUAN ZHOU; LEE, Sungryul et al.Cardiovascular drugs and therapy. 2011, Vol 25, Num 4, pp 299-306, issn 0920-3206, 8 p.Article

A Fission Yeast-Based Platform for Phosphodiesterase Inhibitor HTSs and Analyses of Phosphodiesterase ActivityDEMIRBAS, Didem; CEYHAN, Ozge; WYMAN, Arlene R et al.Handbook of experimental pharmacology. 2011, Vol 204, pp 135-149, issn 0171-2004, 15 p.Article

The Successful Use of Phosphodiesterase Type 5 Inhibitors to Treat the Syndrome of Cor Pulmonale and Prerenal Azotemia with Diuresis of Anasarca (CorPRADA)BEREZ, Paul Bruce.Southern medical journal (Birmingham, Ala. Print). 2010, Vol 103, Num 2, pp 116-120, issn 0038-4348, 5 p.Article

Assessment of a new in vitro maturation system for mouse and human cumulus-enclosed oocytes: three-dimensional prematuration culture in the presence of a phosphodiesterase 3-inhibitorVANHOUTTE, L; NOGUEIRA, D; DUMORTIER, F et al.Human reproduction (Oxford. Print). 2009, Vol 24, Num 8, pp 1946-1959, issn 0268-1161, 14 p.Article

Effect of phosphodiesterase-5 inhibitor on hearingOKUYUCU, S; GUVEN, O. E; AKOGLU, E et al.Journal of laryngology and otology. 2009, Vol 123, Num 7, pp 718-722, issn 0022-2151, 5 p.Article

Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysisTSERTSVADZE, Alexander; FINK, Howard A; FOX, Steven et al.Annals of internal medicine. 2009, Vol 151, Num 9, pp 650-661, issn 0003-4819, 12 p.Article

Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunctionSADOVSKY, R; BROCK, G. B; GUTKIN, S. W et al.International journal of clinical practice (Esher). 2009, Vol 63, Num 8, pp 1214-1230, issn 1368-5031, 17 p.Article

Recovery of respiratory activity after C2 hemisection (C2HS): Involvement of adenosinergic mechanismsNANTWI, Kwaku D.Respiratory physiology & neurobiology. 2009, Vol 169, Num 2, pp 102-114, issn 1569-9048, 13 p.Article

A typology of men's sexual attitudes, erectile dysfunction treatment expectations and barriersBERNER, M. M; PLOGER, W; BURKART, M et al.International journal of impotence research. 2007, Vol 19, Num 6, pp 568-576, issn 0955-9930, 9 p.Article

Phosphodiesterase 5 inhibitors : Drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles : Phosphodiesterase 5 inhibitors : pharmacology and therapeutic perspectivesSUPURAN, Claudiu T; MASTROLORENZO, Antonio; BARBARO, Giuseppe et al.Current pharmaceutical design. 2006, Vol 12, Num 27, pp 3459-3465, issn 1381-6128, 7 p.Article

Mind the gap: Delayed manifestation of long-term object memory improvement by phosphodiesterase inhibitorsAKKERMAN, S; BLOKLAND, A; PRICKAERTS, J et al.Neurobiology of learning and memory (Print). 2014, Vol 109, pp 139-143, issn 1074-7427, 5 p.Article

Effects of phosphodiesterase type 5 inhibitors on endothelial function and cardiovascular autonomic nerve function in menSTIRBAN, Alin; TAMLER, Ronald; ANDREI VERESIU, Loan et al.Journal of men's health (Print). 2011, Vol 8, Num 2, pp 109-118, issn 1875-6867, 10 p.Article

  • Page / 43